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Abstract. The role of base excision repair (BER) genes in 
Philadelphia-negative (PN)-myeloproliferative neoplasms 
(MPNs) susceptibility was evaluated by genotyping eight 
polymorphisms [apurinic/apyrimidinic endodeoxyribo-
nuclease 1, mutY DNA glycosylase, earlier mutY homolog 
(E. coli) (MUTYH), 8-oxoguanine DNA glycosylase 1, poly 
(ADP-ribose) polymerase (PARP) 1, PARP4 and X-ray repair 
cross-complementing 1 (XRCC1)] in a case-control study 
involving 133 Caucasian Portuguese patients. The results did 
not reveal a correlation between individual BER polymor-
phisms and PN-MPNs when considered as a whole. However, 
stratification for essential thrombocythaemia revealed 
i) borderline effect/tendency to increased risk when carrying 
at least one variant allele for XRCC1_399 single-nucleotide 
polymorphism (SNP); ii) decreased risk for Janus kinase 
2-positive patients carrying at least one variant allele for 
XRCC1_399 SNP; and iii) decreased risk in females carrying 
at least one variant allele for MUTYH SNP. Combination of 
alleles demonstrated an increased risk to PN-MPNs for one 
specific haplogroup. These findings may provide evidence 
for gene variants in susceptibility to MPNs. Indeed, common 
variants in DNA repair genes may hamper the capacity to 
repair DNA, thus increasing cancer susceptibility.
Introduction
Among myeloproliferative neoplasms (MPNs), and 
besides chronic myelogenous leukemia, the World 
Health Organization (WHO) classification includes 
Philadelphia-negative (PN)-MPNs, namely, polycythaemia 
vera (PV), essential thrombocythaemia (ET) and primary 
myelofibrosis (PMF) (1,2).
Major genetic insights into the pathogenesis of PN-MPNs 
include the identification of somatic point gain‑of‑function 
mutations in the Janus kinase 2 (JAK2) gene (V617F muta-
tion in exon 14 first in 2005, then in exon 12) (3-7) and the 
myeloproliferative leukemia virus oncogene (most frequently 
W515), in addition to recently identified calreticulin muta-
tions (8-11), with implications in the understanding of 
these diseases, their diagnosis and management. The corre-
sponding frequencies of these mutations are ~95, 0 and 0% 
in PV; 60, 3 and 20% in ET; and 60, 7 and 25% in PMF, 
respectively (12,13).
Those mutations, however, could not fully explain 
the phenotypic heterogeneity of PN‑MPNs. Furthermore, 
genetic defects still await identification in ~40% of ET 
and PMF cases (12-14). Single-nucleotide polymorphisms 
(SNPs) at various loci and additional somatic genetic 
effects may be important for PN‑MPNs phenotype defini-
tion and for prognosis evaluation, although less specific 
than known variations (12-16). Not all mutations involved 
in cancer initiation may lead to cancer. This can occur due 
to different variants within the same gene or between vari-
ants in different genes. The latter must be considered, as the 
number of passenger mutations in a tumour may modulate 
the effect of driver mutations, thus acting as putative modi-
fier genes (17). Additionally, epimutations that can silence 
tumour-suppressor genes must be taken into account (17), 
which highlights the concept that, probably more important 
than the genes, are their levels of expression.
MPNs have high morbidity with thrombohaemorrhagic 
complications and risk of progression to acute myeloid 
DNA repair genes polymorphisms and genetic 
susceptibility to Philadelphia-negative myeloproliferative 
neoplasms in a Portuguese population: The role of 
base excision repair genes polymorphisms
ANA P. AZEVEDO1,2,  SUSANA N. SILVA1,  JOÃO P. DE LIMA1,  ALICE REICHERT3,  
FERNANDO LIMA3,  ESMERALDINA JÚNIOR2  and  JOSÉ RUEFF1
1Centre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical 
School, Faculty of Medical Sciences, NOVA University of Lisbon, 1169‑056 Lisbon; Departments of 2Clinical Pathology 
and 3Clinical Haematology, Hospital of São Francisco Xavier, West Lisbon Hospital Centre, 1449‑005 Lisbon, Portugal
Received September 27, 2016;  Accepted January 26, 2017
DOI: 10.3892/ol.2017.6065
Correspondence to: Professor Susana N. Silva, Centre for 
Toxicogenomics and Human Health (ToxOmics), Genetics, 
Oncology and Human Toxicology, NOVA Medical School, Faculty 
of Medical Sciences, NOVA University of Lisbon, Campo dos 
Mártires da Pátria 130, 1169-056 Lisbon, Portugal
E-mail: snsilva@nms.unl.pt; jose.rueff@nms.unl.pt
Key words: Philadelphia-negative myeloproliferative neoplasms, 
genetic susceptibility, base excision repair genes polymorphisms, 
DNA repair
AZEVEDO et al:  MYELOPROLIFERATIVE NEOPLASMS SUSCEPTIBILITY4642
leukemia (AML), in occasions preceded by a phase of myelo-
fibrosis or myelodysplastic syndromes (MDS) (18). Life 
expectancy in patients with PV or ET is reduced compared 
with that in the general population (19,20). The ‘true’ rate of 
transformation is not accurate due to selection bias in clinical 
trials and underreporting in population-based studies (21). 
The occurrence of leukemia in ET and PV is associated with 
a bad prognosis, and has been reported to occur in 5-10% 
of patients 10 years following the initial diagnosis (1,22). 
It is well known that high doses of alkylating agents and 
combined cytoreductive treatments undoubtedly increase the 
risk of malignant transformation (23). However, there is also 
an intrinsic propensity in MPNs to progress to AML/MDS, 
in an extent that is not fully known (23,24). It cannot be ruled 
out that mutational burden, polymorphic variants of several 
genes, ambient/dietary exposure and immune system char-
acteristics could be predisposing factors to susceptibility to 
these disorders (14,25-28).
DNA damage to haematopoietic precursor cells would 
appear to be essential for the development of leukaemia, 
notwithstanding DNA repair systems act to repair the DNA 
damage, thus maintaining genetic integrity (29,30).
Several polymorphisms in DNA repair genes have been 
identified that may affect protein function and thus DNA 
damage repair, leading to susceptibility to malignancy, in 
spite of their low genetic penetrance (25,29-32). Previous 
reports have identified base excision repair (BER) genes 
polymorphisms associated with breast and thyroid cancer 
risk (33-35) among other malignancies, and a nucleotide 
excision repair gene polymorphism displayed strong asso-
ciation with leukaemic transformation and development of 
non-myeloid malignancies in patients with ET and PV (24).
The BER pathway typically repairs a small region 
(1-13 nucleotides) around the damaged base, involving 
apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1), 
8-oxoguanine DNA glycosylase 1 (OGG1), poly (ADP-ribose) 
polymerase (PARP) 1 or X-ray repair cross-complementing 1 
(XRCC1) (36).
Several SNPs in genes of the BER pathway [APEX1, mutY 
DNA glycosylase, earlier mutY homolog (E. coli) (MUTYH), 
OGG1, PARP1, PARP4 and XRCC1] have been identified and 
studied for their association with the risk of leukaemia and 
disease outcome (25,30,37).
A wider characterization of molecular genetic features 
in PN-MPNs may contribute to a better understanding of 
the pathogenesis of these diseases and provide new specific 
diagnostic, prognostic and therapeutic tools (14).
Since data on the role of BER gene variants in PN-MPNs 
are absent in the literature, the present study describes a 
hospital-based, case-control study in a Caucasian Portuguese 
population in order to help assessing a possible role of BER 
genes on the individual susceptibility to PN-MPNs.
Materials and methods
Study subjects. The present case-control study involved 
133 Caucasian Portuguese PN-MPNs patients (80 with ET, 
39 with PV and 14 with PMF) in addition to 281 age‑ and 
gender-matched controls selected within the Portuguese 
population, who were recruited between January 2009 
and July 2016, followed and treated at the Departments of 
Clinical Haematology and Clinical Pathology, Hospital of 
São Francisco Xavier, West Lisbon Hospital Centre (Lisbon, 
Portugal), a public general hospital that provides healthcare 
to the western population of Lisbon. Diagnosis criteria 
for all patients were those updated by the WHO (38). For 
all cases, at least two control individuals (n=281) without 
neoplastic pathology, and matched for age (±2 years), gender 
and ethnicity were recruited, who had no personal or family 
history of PN-MPNs, no previous or current malignant 
disease and no history of blood transfusions. All patients 
and controls in the study were Portuguese, with Portuguese 
ascendants. For each patient and control, information was 
recorded concerning demographic characteristics, family 
history of cancer, lifestyle habits (e.g. tobacco smoking and 
alcohol consumption) and exposure to ionizing radiation. 
Concerning tobacco smoking habits, former smokers were 
considered as non-smokers if they had stopped smoking 
either 2 years prior to PN-MPN diagnosis in the case of 
patients or 2 years prior to the inclusion date in the study in 
the case of controls. The recorded information was coded to 
assure anonymity of the participants, and written informed 
consent was obtained from all those involved, prior to blood 
withdrawal, in agreement with the Declaration of Helsinki. 
The present study was also conducted with approval by the 
institutional ethics' boards of the involved institutions (NOVA 
Medical School and Hospital de São Francisco Xavier, Centro 
Hospitalar de Lisboa Ocidental). General characteristics for 
PN-MPNs patients and control populations are summarized 
in Tables I and II.
DNA extraction. DNA was obtained from cells of periph-
eral blood samples through a commercially available kit 
(QIAamp® DNA Mini kit; Qiagen GmbH, Hilden, Germany) 
according to the manufacturer's protocol. All DNA samples 
collected were stored at ‑20˚C until analysis.
SNP selection. The appropriate SNPs analyzed in the present 
study were selected concerning their relevance in the DNA 
repair pathway (33,34). All SNPs had a minor allele frequency 
of >0.1 in Caucasian populations (Table III).
Genotyping. The polymorphisms rs1130409 (APEX1), 
rs3219489 (MUTYH), rs1052133 (OGG1), rs1136410 (PARP1), 
rs13428 and rs1050112 (PARP4), and rs1799782 and rs25487 
(XRCC1) were genotyped using real-time PCR reaction in a 
7300 Real-Time PCR system (Applied Biosystems; Thermo 
Fisher Scientific, Inc., Waltham, MA, USA) with TaqMan® 
SNP Genotyping Assays (Thermo Fisher Scientific, Inc.), 
according to the manufacturer's protocol and to previous 
reports from our group and using primers from the Taqman 
kit (33,39-42), with a minor modification where the final 
volume of the reaction was adjusted to 10 µl. RT-PCR geno-
type determinations were conducted in 20% of samples in 
independent experiments (60 randomly selected individuals 
for the control group and 30 for the case group), and all the 
inconclusive samples were reanalyzed. Table III summarizes 
the information on the SNP genotyping assay.
JAK2 V617F mutational status was determined using 
RT-PCR in a 7300 Real-Time PCR system with TaqMan® 
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SNP Genotyping Assays according to the manufacturer's 
protocol.
Statistical analysis. The analysis of Hardy-Weinberg frequen-
cies for all alleles in the enrolled populations was carried 
out using exact probability tests available in SNPstat website 
software (http://bioinfo.iconcologia.net/SNPstats) (43). 
Differences in genotype frequency, tobacco smoking/alcohol 
consumption status, age class and gender distributions 
between PN-MPNs cancer patients and controls were evalu-
ated by the χ2 test. The crude and adjusted odds ratios (ORs) 
corresponding to 95% confidence intervals (CIs) were 
calculated by unconditional multiple logistic regression and 
statistical analysis performed with SPSS version 22.0 (IBM 
SPSS, Armonk, NY, USA). The adjusted OR was determined 
correcting the results for gender, age at diagnosis, and 
tobacco smoking and alcohol consumption habits.
Since the present study is not a conclusive final study, but 
an exploratory one, on the role of BER polymorphisms in 
PN-MPNs, and the data obtained should be considered as 
proof of concept on that possible role, the Bonferroni adjust-
ment was deemed as not necessary, as it is too conservative.
Results
Characterization of populations. The present study included 
133 PN-MPNs patients and 281 age- and gender-matched 
controls. According to the diagnosis criteria, the patients' 
distribution was as follows: 80 patients (60.2%) with ET, 39 
(29.3%) with PV and 14 (10.5%) with PMF (Table II). The 
baseline characteristics (gender, age, alcohol consumption 
and tobacco smoking habits) of the case and control popula-
tions are listed in Tables I and II.
The case group included 72 (54.1%) females and 61 
(45.9%) males, with an overall mean age of 68 years, in 
agreement with the gender distribution usually observed in 
this type of pathology (1,44). No significant differences were 
observed between the control and patient groups concerning 
age distribution or tobacco smoking habits (Table I). However, 
Table I. General characteristics of the Philadelphia-negative myeloproliferative neoplasm cases (n=133) and control population 
(n=281).
Characteristics Cases, n (%) Controls, n (%) P-valuec
Gender   0.780
  Male 61 (45.9) 133 (47.3)
  Female 72 (54.1) 148 (52.7)
Age, yearsa,b   0.622
  30-49 16 (12.0) 43 (15.3)
  50-69 50 (37.6) 107 (38.1)
  ≥70 67 (50.4) 131 (46.6)
Tobacco smoking habits   0.633
  Never 104 (78.2) 213 (76.1) 
  Current 29 (21.8) 67 (23.9)
Alcohol consumption habits   <0.0001
  Never 103 (77.4) 191 (68.2)
  Social 20 (15.0) 25 (8.9)
  Regular 10 (7.5) 64 (22.9)
JAK2 V617F mutation   0.020
  Yes 99 (75.0)
    ET 58 (73.4)
    PV 34 (87.2)
    PMF 7 (50.0)
  No 33 (25.0)
aAge at diagnosis for cases. bAge of control population at the time of diagnosis for the matched case. cP-value determined by χ2 test. ET, 
essential thrombocythaemia; PV, polycythaemia vera; PMF, primary myelofibrosis.
Table II. Gender distribution for the Philadelphia-negative 
myeloproliferative neoplasm cases (n=133).
Diagnosis Patients, n Male, n (%) Female, n (%)
ET 80 32 (40.0) 48 (60.0)
PV 39 20 (51.3) 19 (48.7)
PMF 14 9 (64.3) 5 (35.7)
ET, essential thrombocythaemia; PV, polycythaemia vera; PMF, 
primary myelofibrosis.
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alcohol consumption was significantly increased in patients 
compared with that in controls (P<0.0001) (Table I).
SNPs genotyping. Of the eight SNPs included in the study, 
only seven were completely genotyped (Table III), since both 
SNPs of the PARP4 gene were in linkage disequilibrium 
(r2>0.80), thus behaving as tag SNPs.
The genotype f requencies determined for a l l 
polymorphisms under study are shown in Table IV. When 
considered individually, no correlation between polymor-
phisms of the BER pathway genes and individual susceptibility 
to PN‑MPNs as a whole could be identified. All the SNPs 
studied were in agreement with the Hardy-Weinberg law 
(P>0.05, exact probability test), with the exception of PARP1 
Val762Ala (P=0.029, exact probability test).
The genotypic frequencies obtained in the control 
populations are similar to those reported previously in other 
Caucasian populations (33,34,40,45).
As shown in Table IV, no significant differences in 
genotypic frequencies were observed for any of the seven 
polymorphisms between cases and controls as a whole 
(P>0.05, χ2 test). However, when the population was 
stratified for pathology status, gender and presence of JAK2 
mutation, a tendency for decrease risk was noticed for 
MUTYH Gln335His and XRCC1 Gln399Arg polymorphisms 
(Table V).
Upon stratification for pathology status, the results 
revealed that, for ET, the presence of at least one variant allele 
for the XRCC1 Gln399Arg gene polymorphism displayed a 
borderline effect on the population (crude OR, 0.623; 95% 
CI, 0.378-1.028; P=0.069) (Table V).
The results demonstrated a decreased risk in the female 
group with ET diagnosis and with at least one variant allele 
for MUTYH Gln335His gene polymorphism (OR, 0.478; 95% 
CI, 0.238-0.962) upon adjustment for potential risk factors 
(Table V).
The relevance of JAK2 mutation in PN-MPNs is well 
known (3-5,7). Therefore, the population was also stratified 
according to the presence of JAK2 mutation in patients, 
showing that the presence of at least one variant allele 
for XRCC1 Gln399Arg gene polymorphism constitutes 
a decreased risk for ET patients (OR, 0.500; 95% CI, 
0.278-0.896) (Table V).
Overall, the results indicate that only XRCC1 Gln399Arg 
and MUTYH Gln335His gene polymorphisms appeared to 
be associated with PN‑MPNs risk. For the remaining poly-
morphisms under study, no significant changes in crude or 
adjusted OR were observed (Tables IV and V).
Haplogroup association. A key point that should be explored in 
studies such as the present one is the effect of the combination 
of all genotypes, since the real situation is the effect of the vari-
ants altogether. The results provided by the SNPstat software 
yielded 60 different combinations, the most frequent of which 
are shown in Table VI. Analyzing the results as haplogroup 
association response, an increased risk to develop a MPN 
was obtained for one specific combination (OR, 3.91; 95% CI, 
1.02-14.95) (Table VII).
Discussion
DNA repair deficiencies and genetic or epigenetic changes may 
decrease the efficiency of DNA repair, thus contributing to 
individual susceptibility to DNA damaging agents and to cancer 
risk (46-48). However, to the best of our knowledge, no clinical 
association studies have been performed to evaluate the role of 
BER pathway polymorphisms on PN-MPNs susceptibility.
The present study revealed a higher incidence of JAK2 
V617F mutation in ET patients and a lower incidence in PV 
patients, compared with that reported in the literature (12,13). 
This finding is probably due to the small population studied and 
to the fact that ET was the most frequent diagnosis among the 
patients included in the current case group.
The present study was intended to ascertain the possible 
role of the genetic polymorphisms APEX1 Asp148Glu, MUTYH 
Gln335His, OGG1 Ser326Cys, PARP1 Val762Ala, PARP4 
Gly1280Arg, and XRCC1 Arg194Trp and Arg399Gln on the 
individual susceptibility for PN-MPNs. The genotypic frequen-
cies of the different SNPs in the control population are similar 
to those reported in other Caucasian populations (33,34,40).
The MUTYH protein acts as a BER glycosylase and is mainly 
involved in the repair of oxidative DNA lesions (34,40,46,49-56). 
MUTYH dysfunction may therefore be of special relevance 
in human tumourigenesis, since it is the only mechanism for 
repairing 8-oxo-dG/adenine mismatches (49). Indeed, two 
specific germline mutations in this gene, Tyr165Cys and 
Gly382Asp, have been associated with a colorectal adenoma 
and carcinoma predisposition syndrome that is now referred 
to as MUTYH-associated polyposis (49). However, various 
others mutations and SNPs have been described to date, for 
which a specific phenotypic consequence is unknown (49). 
An example of one common SNP in the MUTYH gene is the 
nonsynonymous Gln335His variation in codon 12 (49,50). The 
enzyme encoded by this variant has been demonstrated to 
have partially impaired glycosylase activity in vitro, and could 
therefore contribute to cancer susceptibility, being much more 
Table III. Selected single-nucleotide polymorphisms and 
detailed information on the corresponding base and amino 
acid exchanges as well as MAF.
  Exchange, base
Gene Codon (amino acid) MAF (%)a
APEX1 148 T→G (Asp/Glu) 44.0
MUTYH 335 G→C (Gln/His) 31.9
OGG1 326 C→G (Ser/Cys) 29.9
PARP1 762 T→C (Val/Ala) 24.4
PARP4 1,280 G→C (Gly/Arg) 45.8
 1,328 C→A (Pro/Thr) 45.8
XRCC1 194 C→T (Arg/Trp) 13.1
 399 G→A (Arg/Gln) 26.6
aAccording to http://www.ncbi.nlm.nih.gov/snp/. MAF, minor allele 
frequency; APEX1, apurinic/apyrimidinic endonuclease 1; MUTYH, 
mutY DNA glycosylase, earlier mutY homolog (E. coli); OGG1, 
8-oxoguanine DNA glycosylase 1; PARP, poly (ADP-ribose) poly-
merase; XRCC1, X-ray repair cross-complementing 1.
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frequently detected in Japanese and Chinese populations than in 
European populations (34,52). The Gln335His variant allele has 
been suggested to be associated with increased risk of colorectal 
cancer (50,52,57) and less consistently with lung cancer (53). For 
the latter, however, existing evidence is conflicting or significant 
only when taking into account gene-gene interactions (53). 
Notably, an almost significant decrease in breast cancer risk 
(OR, 0.80; 95% CI, 0.59-1.07) was described previously by our 
group in MUTYH Gln335His heterozygotes (40). Furthermore, 
gene-gene interactions among BER polymorphisms were 
observed in ever tobacco smokers in a bladder cancer suscep-
tibility study (54). Those previous results suggest that genetic 
variation in BER genes may contribute to cancer risk through 
gene-gene and gene-environmental interactions.
To the best of our knowledge, there are no clinical asso-
ciation studies in which the role of the MUTYH Gln335His 
Table IV. Genotype distribution and myeloproliferative risk for the APEX1 Asp148Glu, MUTYH Gln335His, OGG1 Ser326Cys, 
PARP1 Val762Ala, PARP4 Gly1280Arg, and XRCC1 Gln399Arg and Arg194Trp polymorphisms in the myeloproliferative 
neoplasms case (n=133) and control (n=281) populations.
Genetic polymorphism Controls, n (%) Cases, n (%) P-valuea OR crude (95% CI) OR adjusted (95% CI)b
APEX1 (Asp148Glu)   0.952  
   Asp/Asp 73 (26.4) 37 (27.8)  1.000 (Reference) 1.000 (Reference)
  Asp/Glu 136 (49.1) 64 (48.1)  0.928 (0.566-1.523) 0.963 (0.580-1.599)
  Glu/Glu 68 (24.5) 32 (24.1)  0.928 (0.521-1.653) 0.923 (0.512-1.663)
  Asp/Glu+Glu/Glu 204 (73.6) 96 (72.2)  0.928 (0.584-1.477) 0.949 (0.591-1.526)
MUTYH (Gln335His)   0.877  
  His/His 142 (51.3) 68 (51.1)  1.000 (Reference) 1.000 (Reference)
  His/Gln 112 (40.4) 52 (39.1)  0.970 (0.626-1.502) 0.902 (0.550-1.413)
  Gln/Gln 23 (8.3) 13 (9.8)   1.180 (0.654-2.471) 1.075 (0.506-2.283)
  His/Gln+Gln/Gln 135 (48.7) 65 (48.9)  1.005 (0.665-1.521) 0.932 (0.609-1.425)
OGG1 (Ser326Cys)   0.545  
  Ser/Ser 182 (65.7) 83 (62.6)  1.000 (Reference) 1.000 (Reference)
  Ser/Cys 83 (30.0) 41 (30.8)  1.083 (0.687-1.708) 1.075 (0.672-1.720)
  Cys/Cys 12 (4.3) 9 (6.8)  1.645 (0.667-4.055) 1.603 (0.631-4.072)
  Ser/Cys+Cys/Cys 95 (34.3) 50 (37.6)  1.154 (0.751-1.774) 1.144 (0.735-1.781)
PARP1 (Val762Ala)   0.769  
  Val/Val 214 (77.0) 104 (78.2)  1.000 (Reference) 1.000 (Reference)
  Val/Ala 63 (22.7) 29 (21.8)  0.947 (0.575-1.559) 1.019 (0.607-1.712)
  Ala/Ala 1 (0.4) 0 (0.0)  ND ND
  Val/Ala+Ala/Ala 64 (23.0) 29 (21.8)  0.932 (0.567-1.533) 1.000 (0.596-1.677)
PARP4 (Gly1280Arg)   0.593  
  Gly/Gly 105 (37.9) 54 (40.6)  1.000 (Reference) 1.000 (Reference)
  Gly/Arg 141 (50.9) 61 (45.9)  0.841 (0.539-1.313) 0.806 (0.510-1.273)
  Arg/Arg 31 (11.2) 18 (13.5)  1.129 (0.579-2.200) 1.000 (0.501-1.997)
  Gly/Arg+Arg/Arg 172 (62.9) 79 (59.4)  0.893 (0.585-1.363) 0.841 (0.543-1.301)
XRCC1 (Arg194Trp)   0.263  
  Arg/Arg 236 (85.5) 121 (91.0)  1.000 (Reference) 1.000 (Reference)
  Arg/Trp 39 (14.1) 12 (9.0)  0.600 (0.303-1.188) 0.650 (0.323-1.307)
  Trp/Trp 1 (0.4) 0 (0.0)  ND ND
  Arg/Trp+Trp/Trp 40 (14.5) 12 (9.0)  0.585 (0.296-1.156) 0.633 (0.315-1.270)
XRCC1 (Gln399Arg)   0.318  
  Arg/Arg 113 (40.8) 61 (45.9)  1.000 (Reference) 1.000 (Reference)
  Arg/Gln 134 (48.4)  54 (40.6)   0.747 (0.479-1.163) 0.762 (0.483-1.204)
  Gln/Gln 30 (10.8) 18 (13.5)  1.111 (0.573-2.155) 1.044 (0.531-2.052)
  Arg/Gln+Gln/Gln 164 (59.2) 72 (54.1)  0.813 (0.536-1.234) 0.818 (0.532-1.255)
aP-value determined by χ2 test. bORs were adjusted for age (30-49, 50-69 and >70 years), tobacco smoking status (never or former and 
current) and alcohol consumption (never, social and regular drinkers). APEX1, apurinic/apyrimidinic endonuclease 1; MUTYH, mutY DNA 
glycosylase, earlier mutY homolog (E. coli); OGG1, 8-oxoguanine DNA glycosylase 1; PARP, poly (ADP-ribose) polymerase; XRCC1, X-ray 
repair cross‑complementing 1; OR, odds ratio; CI, confidence interval; ND, none determined.
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polymorphism had been evaluated on PN-MPNs susceptibility. 
The results reported in the present study suggest that, when 
considering females with ET, a consistent decrease in overall 
PN-MPNs risk was observed when at least one variant allele 
carrying MUTYH Gln335His is present (Table V).
The XRCC1 nuclear protein serves an important role in 
assisting and enabling the repair of single-strand breaks by 
interacting and recruiting to the DNA lesion sites multiple 
enzymatic components of repair reactions (58). Arg194Trp and 
Arg399Gln polymorphisms are among the most extensively 
Table V. ORs (95% CI) for MUTYH (Gln335His) and XRCC1 _399 (Gln399Arg) polymorphisms and Philadelphia-negative 
myeloproliferative neoplasms association.
Pathology stratification Patients, n SNP P‑valuea OR crude (95% CI) OR adjusted (95% CI)b
ET 80 XRCC1_399  0.166  
  (Gln399Arg; rs25487)
  Arg/Arg  1.000 (Reference) 1.000 (Reference)
  Arg/Gln   0.602 (0.354-1.025)i 0.611 (0.355-1.053)i
  Gln/Gln  0.717 (0.305-1.690) 0.667 (0.279-1.595)
  Arg/Gln+Gln/Gln  0.623 (0.378-1.028)i 0.622 (0.373-1.038)i
ET, females 48 MUTYH  0.015  
  (Gln335His; rs3219489)
  His/His  1.000 (Reference) 1.000 (Reference)
  His/Gln   0.342 (0.152-0.773)c 0.325 (0.142-0.744)d
  Gln/Gln  1.331 (0.480-3.692) 1.229 (0.435-3.475)
  His/Gln+Gln/Gln  0.507 (0.256-1.003)i 0.478 (0.238-0.962)j
ET, JAK2 58 XRCC1_399  0.044  
  (Gln399Arg; rs25487)
  Arg/Arg  1.000 (Reference) 1.000 (Reference)
  Arg/Gln   0.471 (0.255-0.871)e 0.490 (0.263-0.915)f
  Gln/Gln  0.554 (0.199-1.538) 0.539 (0.192-1.514)
  Arg/Gln+Gln/Gln  0.486 (0.274-0.864)g 0.500 (0.278-0.896)h
aP-value determined by χ2 test. bORs were adjusted for age (30-49, 50-69 and >70 years), tobacco smoking status (never or former and 
current) and alcohol consumption (never, social and regular drinkers). cPcrude=0.010; dPadjusted=0.008 (P-values are adjusted by unconditional 
multiplicative logistic regression). ePcrude=0.016; fPadjusted=0.025 (P-values are adjusted by unconditional multiplicative logistic regression). 
gPcrude=0.014; hPadjusted=0.020 (P-values are adjusted by unconditional multiplicative logistic regression). iRepresents results that almost reached 
the significance threshold, demonstrating a borderline effect. jPadjusted=0.039 (P-values are adjusted by unconditional multiplicative logistic 
regression). SNP, single‑nucleotide polymorphism; OR, odds ratio; CI, confidence interval; MUTYH, mutY DNA glycosylase, earlier mutY 
homolog (E. coli); XRCC1, X-ray repair cross-complementing 1; ET, essential thrombocythaemia; JAK2, Janus kinase 2.
Table VI. Haplogroup frequencies for the single-nucleotide polymorphisms under study.
 Haplogroup estimation Haplogroup
--------------------------------------------------------------------------------------------------------------------------------------------------------------------- frequencies
APEX MUTYH OGG1 PARP1 PARP4 XRCC1_194 XRCC1_399 Global ---------------------------------
D148E Q335H S326C V762A G1,280R R194W R399Q frequency Controls Cases
D H S V G R R 0.116 0.167 0.068
E H S V G R R 0.084 0.060 0.130
E H S V G R Q 0.069 0.065 0.062
E H S V R R R 0.050 0.058 0.044
D H S V R R Q 0.045 0.036 0.060
D H S V R R R 0.045 0.030 0.060
E H C V G R R 0.033 0.025 0.042
E Q S V R R R 0.032 0.028 0.053
APEX1, apurinic/apyrimidinic endonuclease 1; MUTYH, mutY DNA glycosylase, earlier mutY homolog (E. coli); OGG1, 8-oxoguanine DNA 
glycosylase 1; PARP, poly (ADP-ribose) polymerase; XRCC1, X-ray repair cross-complementing 1.
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studied SNPs in the XRCC1 gene (25,29,30,33-35,37,46,51, 
53-55,59-63). These two SNPs have been shown to alter 
the functional activity of the resulting protein in vitro and 
to interfere with cancer susceptibility. The Arg194Trp 
variant allele has been associated with decreased risk of 
certain cancers, particularly among tobacco smokers (59). 
Conversely, the Arg399Gln variant allele has been suggested 
to be associated with decreased DNA repair capacity and 
higher sensitivity to genotoxicants compared with the 
Arg194Trp variant allele (64). However, previous epide-
miological results have been inconsistent and dependent 
on the cancer type (51,65,66). Several interactions such as 
gene-environment (e.g. alcohol consumption or menopausal 
age) and gene-gene (e.g. other DNA repair or chemical metab-
olizing enzymes) have also been reported for both SNPs (46). 
However, several well-powered studies and meta-analyses 
have not confirmed these supposed effects (46,60). Generally, 
the results reported to date suggest a modest impact of both 
XRCC1 gene polymorphisms on protein activity and cancer 
susceptibility. However, certain studies have suggested that 
they may represent a risk factor for haematological malig-
nancies such as leukaemia, according to previous studies 
on XRCC1 polymorphisms in association with AML, acute 
lymphoblastic leukaemia, chronic lymphocytic leukaemia 
and lymphoma (25,29,30). The present results support a 
borderline effect for ET patients and a protective effect 
in overall PN-MPNs risk when considering ET patients 
presenting JAK2 mutation, as observed under the presence 
of at least one variant allele carrying XRCC1 Arg399Gln 
(Table V). Although the Arg194Trp allele did not show any 
association with the risk of developing PN-MPNs, it should 
be noted that the Arg194Trp variant allele may be associated 
with higher DNA repair capacity, lower sensitivity to gent-
oxicants and decreased risk of other cancers, when compared 
with other variants. In addition, other factors may influence 
the biological effect of the Arg194Trp polymorphism, such 
as disease development stage, specific environmental factors 
and even different genetic background among populations. 
In order to clarify the role of XRCC1 polymorphisms in 
PN-MPNs susceptibility, larger studies and/or a meta-anal-
ysis are required.
Regarding the OGG1 Ser326Cys polymorphism, the current 
results did not reveal a significant contribution on individual 
susceptibility towards PN-MPNs (Tables III and IV). The 
OGG1 Ser326Cys polymorphism has been demonstrated to 
impair protein function (46), and therefore, it has been widely 
evaluated in different case-control studies (67). Significant 
results were observed in lung (59,68), head and neck (69,70), 
colorectal (51,71) and gallbladder cancer (65,72). However, 
several previous meta-analyses (68,70,73-76) did not reveal any 
significant association between this OGG1 polymorphism and 
other cancers risk.
Human APEX1 is a multifunctional enzyme that holds 
complementary key roles in cancer. Notably, this enzyme is 
a crucial component of the BER pathway due to its ability to 
process AP sites and other 3'DNA termini that may result, for 
example, from exposure to ionizing radiation or direct attack 
by free radicals (59,77,78). Among the 18 identified SNPs for 
the APEX1 gene, the most studied one is the T>G transition 
at codon 148 of exon 5, which leads to a change in amino acid 
from Asp to Glu (56). Its potential role on cancer was evaluated 
in four meta-analyses on breast cancer susceptibility (55,79-81), 
two meta-analyses on prostate cancer (82,83) and several 
studies on other types of cancer (84-87). However, the results 
published remain inconclusive. Concerning the present results, 
the association of APEX1 Asp148Glu with PN-MPNs risk did 
not exhibit any association.
PARP1 is an abundant nuclear protein that can bind to 
DNA and promote the poly (ADP-ribosylation) of a variety 
of proteins. PARP1 acts on single- and double-stranded DNA 
breaks by recruiting DNA repair factors (88). It has a major 
signaling role in DNA damage detection and repair, acting as a 
molecular nick sensor to initiate the recruitment of XRCC1 and 
the assembly of the single-strand break repair machinery (89). 
PARP1 Val762Ala is one of the most common nonsynony-
mous SNPs studied in this gene, resulting in an amino acid 
Table VII. Haplogroup association response for the single-nucleotide polymorphisms under study.
 Haplotype association response
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------
APEX MUTYH OGG1 PARP1 PARP4 XRCC1_194 XRCC1_399
D148E Q335H S326C V762A G1280R R194W R399Q OR (95% CI) P-value
D H S V G R R 1.00 (Reference)
E H S V G R R 3.17 (0.99-10.17) 0.05
E H S V G R Q 0.92 (0.34-2.53) 0.88
E H S V R R R 1.55 (0.50-4.76) 0.45
D H S V R R Q 2.13 (0.60-7.53) 0.24
D H S V R R R 1.90 (0.41-8.79) 0.41
E H C V G R R 3.41 (0.87-13.36) 0.08
E Q S V R R R 3.91 (1.02-14.95) 0.05a
APEX1, apurinic/apyrimidinic endonuclease 1; MUTYH, mutY DNA glycosylase, earlier mutY homolog (E. coli); OGG1, 8-oxoguanine DNA 
glycosylase 1; PARP, poly (ADP‑ribose) polymerase; XRCC1, X‑ray repair cross‑complementing 1; OR, odds ratio; CI, confidence interval. 
aP<0.047.
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substitution within the COOH-terminal catalytic domain of the 
enzyme (90,91). This variant has been associated with reduced 
enzymatic activity (61) and limited capacity for interaction 
with XRCC1 (62). This may result in decreased BER capacity, 
thus increasing cancer predisposition in PARP1 Val762Ala 
carriers. Indeed, this variant form has been associated in 
various well-powered clinical association studies with increased 
cancer susceptibility, namely to lung (61) and gastrointestinal 
tract (62,92) cancer, while Adel Fahmideh et al (74) described 
a decreased risk for glioma associated with this SNP. Studies 
regarding other types of cancer such as breast cancer (55,63) 
failed to demonstrate an association between PARP1 Val762Ala 
and cancer susceptibility. The present results do not suggest 
any association between PARP1 Val762Ala polymorphism and 
PN-MPNs risk (Table IV).
Concerning the analysis of haplogroups' association 
response, an increased risk to PN-MPNs could be observed 
for one specific combination (Table VII). This result should, 
however, be taken with care when evaluating this parameter 
risk for PN-MPNs due to its low frequency (3.2%) in the studied 
population, even though it may represent a tendency on how 
SNPs in BER genes influence PN‑MPNs.
Overall, the present results reveal that the XRCC1 
Gln399Arg and MUTYH Gln335His gene polymorphisms 
appear to be associated with PN‑MPNs risk. For all other poly-
morphisms under study, no significant change was observed 
(Tables IV and V).
Although certain published studies consider tobacco 
smoking as a contributing factor for PN-MPNs (93,94), the 
present study did not reveal an important association, probably 
due to the small number of tobacco smokers included.
Additional studies involving larger populations should be 
conducted to further clarify the potential value of the different 
BER genotypes as predictive biomarkers of susceptibility to 
PN-MPNs and to study gene-environment and gene-gene inter-
actions. In addition, stratified analysis according to histological 
subtype and disease stage should be conducted.
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